Por décadas, a enxaqueca foi subestimada como simples dor de cabeça, enquanto milhões de brasileiros enfrentavam crises incapacitantes sem respostas terapêuticas suficientes. A Anvisa aprovou na segunda-feira o Nurtec ODT, da Pfizer, um medicamento que inaugura uma nova classe de tratamento ao bloquear a proteína CGRP — responsável pela cascata inflamatória que origina a dor. A aprovação oferece, pela primeira vez, uma opção que age tanto no alívio agudo quanto na prevenção das crises, reconhecendo a enxaqueca como a doença neurológica séria que sempre foi.
CNN Brasil
· May 25, 2026
· health
· 1 min read
High
Sourcing: Verified
Anvisa aprova Nurtec ODT, novo medicamento para tratamento de enxaqueca
Migraine sufferers experiencing moderate to severe headaches with nausea, vomiting, and light/sound sensitivity gain access to a new treatment option.
◉
Health & Medicine
2697 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% match
Berlin admits American Ebola patient as outbreak kills 131 in Congo
Folha de S.Paulo · 90% match
Related Coverage
Folha de S.Paulo · Aug 18
Cisne mantém reinado como melhor sal entre paulistanos pela quinta vez
A marca Cisne vence pela quinta vez consecutiva a pesquisa Datafolha como melhor sal entre paulistanos, com 50% das menç…
Folha de S.Paulo · Aug 18 Projeto Quebrada Alimentada é eleito iniciativa de destaque em gastronomia pela FolhaO projeto Quebrada Alimentada, nascido no restaurante Mocotó durante a pandemia, foi eleito iniciativa de destaque pela …
UOL · Aug 17 Lucy Ramos revela que Globo consultou obstetra para cena de acidente na novelaA atriz Lucy Ramos revelou que a Globo consultou seu obstetra antes de gravar uma cena de acidente fatal enquanto ela es…
Estadão · Aug 17 Asma não impede atividade física; exercício regular ajuda no controle da doençaPesquisas confirmam que atividade física beneficia asmáticos, mas requer controle da doença e atenção a fatores ambienta…
Bias & Framing
⚖
Straightforward regulatory approval announcement with factual medical information, minimal bias detected in presentation of Pfizer's migraine drug approval.
Bias Direction
center
Confidence
HIGH
Standard health/regulatory news framing: factual announcement of approval with medical details and disease context. Presents information neutrally without advocacy or criticism.
Patient testimonials or real-world experiences
Cost/accessibility information for Brazilian patients
Comparative efficacy data versus existing treatments
Potential side effects or safety concerns
Healthcare provider perspectives on the approval
Public health impact assessment
Geopolitical Impact
🌎
Anvisa's approval of Pfizer's Nurtec ODT represents routine pharmaceutical regulatory action with minimal geopolitical significance.
Escalation Risk
low
Confidence
HIGH
Brazil
No meaningful shift. This is a standard pharmaceutical approval demonstrating Brazil's regulatory capacity and continued integration into global pharmaceutical markets dominated by major Western companies like Pfizer.
Economic Lens
📈
Anvisa approved Pfizer's Nurtec ODT, a novel CGRP-blocking migraine treatment, expanding pharmaceutical options for chronic migraine patients in Brazil's healthcare market.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Services
Medical Devices & Diagnostics
Brazilian migraine sufferers gain access to innovative treatment with potentially better efficacy and tolerability; may reduce healthcare costs from migraine-related productivity losses and emergency visits, though drug pricing will determine accessibility across income levels.
Anvisa's approval signals regulatory openness to novel therapeutic mechanisms; potential implications for pricing negotiations with ANVISA/CONITEC, insurance coverage decisions, and consideration of inclusion in public healthcare (SUS) formularies for chronic migraine management.